Impaired postprandial fibroblast growth factor (FGF)-19 response in patients with stage 5 chronic kidney diseases is ameliorated following antioxidative therapy

Nephrology Dialysis Transplantation

Volumn 28, Issue SUPPL.4, 2013, Pages

  Li, Meng ^a   Qureshi, Abdul Rashid ^a   Ellis, Ewa ^b   Axelsson, Jonas ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Karolinska Institutet ^*  (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CKD; FGF 19; Glucose; Hormones; Insulin resistance; MP865; N acetyl cysteine; Postprandial

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; C PEPTIDE; FIBROBLAST GROWTH FACTOR 19; GLUCOSE; INSULIN; MP 865; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HUMAN; MALE; METABOLIC DISORDER; MIDDLE AGED; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UPREGULATION;

CKD; FGF-19; GLUCOSE; HORMONES; INSULIN RESISTANCE; MP865; N-ACETYL CYSTEINE; POSTPRANDIAL;

ACETYLCYSTEINE; ADULT; AGED; ANTIOXIDANTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLUEBERRY PLANT; CASE-CONTROL STUDIES; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; INSULIN; MALE; MIDDLE AGED; PHYTOTHERAPY; POSTPRANDIAL PERIOD; PROGNOSIS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TRIGLYCERIDES; YOUNG ADULT;

EID: 84890099702     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft337     Document Type: Article

References (32)

1. Neirynck N, Eloot S, Glorieux G et al. Estimated glomerular filtration rate is a poor predictor of the concentration of middle molecular weight uremic solutes in chronic kidney disease. PLoS One 2012; 7: e44201
2. Christensen EI, Birn H, Storm T et al. Endocytic receptors in the renal proximal tubule. Physiology (Bethesda) 2012; 27: 223-36
3. Kir S, Beddow SA, Samuel VT et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011; 331: 1621-1624
4. Axelsson J, Witasp A, Carrero JJ et al. Circulating levels of visfatin/ pre-B-cell colony-enhancing factor 1 in relation to genotype,GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 2007; 49: 237-44
5. Siew ED, Pupim LB, Majchrzak KM et al. Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int 2007; 71: 146-52
6. Wasada T, Inoue K, Fujimi S et al. Hypersomatostatinemia in chronic renal failure. Endocrinol Jpn 1987; 34: 251-6
7. Rodriguez Ayala E, Pecoits-Filho R, Heimburger O et al. Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. Nephrol Dial Transplant 2004; 19: 421-6
8. Miyamoto T, Rashid Qureshi A, Yamamoto T et al. Postprandial metabolic response to a fat- and carbohydrate-rich meal in patients with chronic kidney disease. Nephrol Dial Transplant 2011; 26: 2231-7
9. Anderstam B, Ann-Christin BH, Valli A et al. Modification of the oxidative stress biomarker AOPP assay: application in uremic samples. Clin Chim Acta 2008; 393: 114-8
10. Seltzer HS, Allen EW, Herron AL, Jr et al. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest 1967; 46: 323-35
11. Keane WF, Tomassini JE, Neff DR. Lipid abnormalities in patients with chronic kidney disease. Contrib Nephrol 2011; 171: 135-42
12. Eidemak I, Feldt-Rasmussen B, Kanstrup IL et al. Insulin resistance and hyperinsulinaemia in mild to moderate progressive chronic renal failure and its association with aerobic work capacity. Diabetologia 1995; 38: 565-72
13. Reiche M, Bachmann A, Lossner U et al. Fibroblast growth factor 19 serum levels: relation to renal function and metabolic parameters.Horm Metab Res 2010; 42: 178-81
14. Habegger KM, Stemmer K, Cheng C et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 2013
15. DeLuca S, Sitara D, Kang K et al. Amelioration of the premature ageing-like features of Fgf-23 knockout mice by genetically restoring the systemic actions of FGF-23. J Pathol 2008; 216: 345-55
16. Ashikaga E, Honda H, Suzuki H et al. Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients.Ther Apher Dial 2010; 14: 315-22
17. Holt JA, Luo G, Billin AN et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003; 17: 1581-91
18. Inagaki T, Choi M, Moschetta A et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217-25
19. Mazza G, Kay CD, Cottrell T et al. Absorption of anthocyanins from blueberries and serum antioxidant status in human subjects. J Agric Food Chem 2002; 50: 7731-7
20. Ramos LF, Shintani A, Ikizler TA et al. Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol 2008; 19: 593-9
21. Stenvinkel P, Carrero JJ, Axelsson J et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3: 505-21
22. Schmidtmann S, Muller M, von Baehr R et al. Changes of antioxidative homeostasis in patients on chronic haemodialysis. Nephrol Dial Transplant 1991; 6(Suppl. 3): 71-4
23. Tepel M, van der Giet M, Schwarzfeld C et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180-4
24. Sun Z, Fu Q, Cao L et al. Intravenous N-acetylcysteine for prevention f contrast-induced nephropathy: a meta-analysis of randomized, controlled trials. PLoS One 2013; 8: e55124
25. Guo H, Ling W, Wang Q et al. Cyanidin 3-glucoside protects3T3-L1 adipocytes against H2O2- or TNF-alpha-induced insulin resistance by inhibiting c-Jun NH2-terminal kinase activation. Biochem Pharmacol 2008; 75: 1393-401
26. Scharfstein JS, Keaney JF, Jr, Slivka A et al. In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. J Clin Invest 1994; 94: 1432-9
27. Quintavalle C, Brenca M, De Micco F et al. In vivo and in vitro assessment of pathways involved in contrast media-induced renal cells apoptosis. Cell Death Dis 2011; 2: e155
28. Min KJ, Lee JT, Joe EH et al. An IkappaBalpha phosphorylation inhibitor induces heme oxygenase-1(HO-1) expression through the activation of reactive oxygen species (ROS)-Nrf2-ARE signaling and ROS-PI3 K/Akt signaling in an NF-kappaB-independent mechanism. Cell Signal 2011; 23: 1505-13
29. Tanioka T, Tamura Y, Fukaya M et al. Inducible nitric-oxide synthase and nitric oxide donor decrease insulin receptor substrate-2 protein expression by promoting proteasomedependent degradation in pancreatic beta-cells: involvement of glycogen synthase kinase-3beta. J Biol Chem 2011; 286: 29388-96
30. Yu Z, Shao W, Chiang Y et al. Oltipraz upregulates the nuclear factor (erythroid-derived 2)-like 2 [corrected](NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice. Diabetologia 2011; 54: 922-34
31. Benzler J, Ganjam GK, Legler K et al. Acute inhibition of central c-Jun N-terminal kinase restores hypothalamic insulin signalling and alleviates glucose intolerance in diabetic mice. J Neuroendocrinol 2013
32. Seltzer HS AE, Herron AL, Jr, Brennan MT. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Investigat 1967; 46: 323-35